Glucosamine-anchored doxorubicin-loaded targeted nano-niosomes: pharmacokinetic, toxicity and pharmacodynamic evaluation

References

• Hortobagyi G. Anthracyclines in the treatment of cancer. Drugs 1997;54:1–7.
   PubMed Web of Science ®Google Scholar
• Kaklamani VG, Gradishar WJ. Epirubicin versus doxorubicin: which is the anthracycline of choice for the treatment of breast cancer? Clin Breast Cancer 2003;4:S26–33.
   PubMedGoogle Scholar
• Thorn CF, Oshiro C, Marsh S, et al. Doxorubicin pathways: pharmacodynamics and adverse effects. Pharmacogenet Genom 2011;21:440–446.
   PubMed Web of Science ®Google Scholar
• Bagchi D, Bagchi M, Hassoun E, et al. Adriamycin-induced hepatic and myocardial lipid peroxidation and DNA damage, and enhanced excretion of urinary lipid metabolites in rats. Toxicology 1995;95:1–9.
   PubMed Web of Science ®Google Scholar
• Xiong X-B, Ma Z, Lai R, Lavasanifar A. The therapeutic response to multifunctional polymeric nano-conjugates in the targeted cellular and subcellular delivery of doxorubicin. Biomaterials 2010;31:757–68.
   PubMed Web of Science ®Google Scholar
• Duncan R, Richardson SC. Endocytosis and intracellular trafficking as gateways for nanomedicine delivery: opportunities and challenges. Mol Pharma 2012;9:2380–402.
   PubMed Web of Science ®Google Scholar
• Sahay G, Alakhova DY, Kabanov AV. Endocytosis of nanomedicines. J Control Release 2010;145:182–95.
   PubMed Web of Science ®Google Scholar
• Greish K. Enhanced permeability and retention of macromolecular drugs in solid tumors: a royal gate for targeted anticancer nanomedicines. J Drug Target 2007;15:457–64.
   PubMed Web of Science ®Google Scholar
• Byrne JD, Betancourt T, Brannon-Peppas L. Active targeting schemes for nanoparticle systems in cancer therapeutics. Adv Drug Deliv Rev 2008;60:1615–26.
   PubMed Web of Science ®Google Scholar
• Webster DM, Sundaram P, Byrne ME. Injectable nanomaterials for drug delivery: carriers, targeting moieties, and therapeutics. Eur J Pharm Biopharm 2013;84:1–20.
   PubMed Web of Science ®Google Scholar
• Pramanik D, Campbell NR, Das S, et al. A composite polymer nanoparticle overcomes multidrug resistance and ameliorates doxorubicin-associated cardiomyopathy. Oncotarget 2012;3:640–50.
   PubMed Web of Science ®Google Scholar
• Tardi P, Boman N, Cullis P. Liposomal doxorubicin. J Drug Target 1996;4:129–40.
   PubMed Web of Science ®Google Scholar
• Fukushima S, Machida M, Akutsu T, et al. Roles of adriamycin and adriamycin dimer in antitumor activity of the polymeric micelle carrier system. Colloids Surf B 1999;16:227–36.
   Web of Science ®Google Scholar
• Khandare J, Minko T. Polymer–drug conjugates: progress in polymeric prodrugs. Prog Polym Sci 2006;31:359–97.
   Web of Science ®Google Scholar
• Tavano L, Vivacqua M, Carito V, et al. Doxorubicin loaded magneto-niosomes for targeted drug delivery. Colloids Surf B Biointerfaces 2013;102:803–7.
   PubMed Web of Science ®Google Scholar
• Liu T, Guo R. Preparation of a highly stable niosome and its hydrotrope-solubilization action to drugs. Langmuir 2005;21:11034–9.
   PubMed Web of Science ®Google Scholar
• Parthasarathi G, Udupa N, Umadevi P, Pillai G. Pharmacokinetic evaluation of surfactant vesicles containing methotrexate in tumor bearing mice. Int J Pharm 1990;61:75–80.
   Google Scholar
• Parthasarathi G, Udupa N, Umadevi P, Pillai G. Niosome encapsulated of vincristine sulfate: improved anticancer activity with reduced toxicity in mice. J Drug Target 1994;2:173–82.
   PubMed Web of Science ®Google Scholar
• Azeem A, Anwer MK, Talegaonkar S. Niosomes in sustained and targeted drug delivery: some recent advances. J Drug Target 2009;17:671–89.
   PubMed Web of Science ®Google Scholar
• Pham TT, Jaafar-Maalej C, Charcosset C, Fessi H. Liposome and niosome preparation using a membrane contactor for scale-up. Colloids Surf B 2012;94:15–21.
   PubMed Web of Science ®Google Scholar
• Mukherjee B, Patra B, Layek B, Mukherjee A. Sustained release of acyclovir from nano-liposomes and nano-niosomes: an in vitro study. Int J Nanomed 2007;2:213–25.
   PubMed Web of Science ®Google Scholar
• Kim D-S, Park K-S, Jeong K-C, et al. Glucosamine is an effective chemo-sensitizer via transglutaminase 2 inhibition. Cancer Lett 2009;273:243–9.
   PubMed Web of Science ®Google Scholar
• Brown JM, Giaccia AJ. The unique physiology of solid tumors: opportunities (and problems) for cancer therapy. Cancer Res 1998;58:1408–16.
   PubMed Web of Science ®Google Scholar
• Wu H-C, Chang D-K, Huang C-T. Targeted therapy for cancer. J Cancer Mol 2006;2:57–66.
   Google Scholar
• Ganapathy V, Thangaraju M, Prasad PD. Nutrient transporters in cancer: relevance to Warburg hypothesis and beyond. Pharmacol Ther 2009;121:29–40.
   PubMed Web of Science ®Google Scholar
• Ferreira LM. Cancer metabolism: the Warburg effect today. Exp Mol Pathol 2010;89:372–80.
   PubMed Web of Science ®Google Scholar
• US20100016249A1. Cancer sensitizer comprising glucosamine, glucosamine derivatives or salts thereof. 2006.
   Google Scholar
• Hulikova K, Svoboda J, Benson V, et al. N-acetyl-D-glucosamine-coated polyamidoamine dendrimer promotes tumor-specific B cell responses via natural killer cell activation. Int Immunopharmacol 2011;11:955–61.
   PubMed Web of Science ®Google Scholar
• Yomogida S, Hua J, Sakamoto K, Nagaoka I. Glucosamine suppresses interleukin-8 production and ICAM-1 expression by TNF-α-stimulated human colonic epithelial HT-29 cells. Int J Mol Med 2008;22:205–11.
   PubMed Web of Science ®Google Scholar
• Uchegbu IF, Vyas SP. Non-ionic surfactant based vesicles (niosomes) in drug delivery. Int J Pharmaceut 1998;172:33–70.
   Web of Science ®Google Scholar
• Pawar S, Vavia P. Glucosamine anchored cancer targeted nano-vesicular drug delivery system of doxorubicin. J Drug Target 2016;24:68–79.
   PubMed Web of Science ®Google Scholar
• Uchimura T, Kato M, Saito T, Kinoshita H. Prediction of human blood-to-plasma drug concentration ratio. Biopharm Drug Dispos 2010;31:286–97.
   PubMed Web of Science ®Google Scholar
• Yoo HS, Lee KH, Oh JE, Park TG. In vitro and in vivo anti-tumor activities of nanoparticles based on doxorubicin-PLGA conjugates. J Control Release 2000;68:419–31.
   PubMed Web of Science ®Google Scholar
• Henry PD, Bloor CM, Sobel BE. Increased serum creatine phosphokinase activity in experimental pulmonary embolism. Am J Cardiol 1970;26:151–5.
   PubMed Web of Science ®Google Scholar
• Husdan H, Rapoport A. Estimation of creatinine by the Jaffe reaction a comparison of three methods. Clin Chem 1968;14:222–38.
   PubMed Web of Science ®Google Scholar
• Pine L, Hoffman P, Malcolm G, et al. Determination of catalase, peroxidase, and superoxide dismutase within the genus Legionella. J Clin Microbiol 1984;20:421–9.
   PubMed Web of Science ®Google Scholar
• Beers RF, Sizer IW. A spectrophotometric method for measuring the breakdown of hydrogen peroxide by catalase. J Biol Chem 1952;195:133–40.
   PubMed Web of Science ®Google Scholar
• Papastergiadis A, Mubiru E, Van Langenhove H, De Meulenaer B. Malondialdehyde measurement in oxidized foods: evaluation of the spectrophotometric thiobarbituric acid reactive substances (TBARS) test in various foods. J Agric Food Chem 2012;60:9589–94.
   PubMed Web of Science ®Google Scholar
• Rahman I, Kode A, Biswas SK. Assay for quantitative determination of glutathione and glutathione disulfide levels using enzymatic recycling method. Nat Protoc 2006;1:3159–65.
   PubMed Web of Science ®Google Scholar
• Zykova M, Ipatova O, Prozorovskii V, et al. Changes of doxorubicin distribution in blood and plasma after its inclusion into nanophospholipid formulations. Biochem (Moscow) Suppl Ser B: Biomed Chem 2012;6:39–41.
   Google Scholar
• Marafino B, Giri S, Siegel D. Pharmacokinetics, covalent binding and subcellular distribution of [3H]doxorubicin after intravenous administration in the mouse. J Pharmacol Exp Ther 1981;216:55–61.
   PubMed Web of Science ®Google Scholar
• Rahman A, Carmichael D, Harris M, Roh JK. Comparative pharmacokinetics of free doxorubicin and doxorubicin entrapped in cardiolipin liposomes. Cancer Res 1986;46:2295–9.
   PubMed Web of Science ®Google Scholar
• Yesair D, Schwartzbach E, Shuck D, et al. Comparative pharmacokinetics of daunomycin and adriamycin in several animal species. Cancer Res 1972;32:1177–83.
   PubMed Web of Science ®Google Scholar
• Danhier F, Feron O, Préat V. To exploit the tumor microenvironment: passive and active tumor targeting of nanocarriers for anti-cancer drug delivery. J Control Release 2010;148:135–46.
   PubMed Web of Science ®Google Scholar
• Mimnaugh EG, Gram TE, Trush MA. Stimulation of mouse heart and liver microsomal lipid peroxidation by anthracycline anticancer drugs: characterization and effects of reactive oxygen scavengers. J Pharmacol Exp Ther 1983;226:806–16.
   PubMed Web of Science ®Google Scholar
• Ayla S, Seckin I, Tanriverdi G, et al. Doxorubicin induced nephrotoxicity: protective effect of nicotinamide. Int J Cell Biol 2011:390238.
   PubMedGoogle Scholar
• Vergely C, Delemasure S, Cottin Y, Rochette L. Preventing the cardiotoxic effects of anthracyclines: from basic concepts to clinical data. Heart Metab 2007;35:1–7.
   Google Scholar
• Rahman AM, Yusuf SW, Ewer MS. Anthracycline-induced cardiotoxicity and the cardiac-sparing effect of liposomal formulation. Int J Nanomed 2007;2:567–83.
   PubMed Web of Science ®Google Scholar
• Bast RC, Kufe DW, Pollock RE, eds. et al. Holland-Frei cancer medicine. 5th ed. 2 v.(xxiv). Hamilton (ON): BC Decker; 2000:2640–99.
   Google Scholar
• Villani F, Galimberti M, Poggi P, et al. The effect of superoxide dismutase and catalase on the delayed toxicity of doxorubicin. Cardiologia (Rome, Italy) 1992;37:709–11.
   PubMedGoogle Scholar
• Kalender Y, Yel M, Kalender S. Doxorubicin hepatotoxicity and hepatic free radical metabolism in rats. The effects of vitamin E and catechin. Toxicology 2005;209:39–45.
   PubMed Web of Science ®Google Scholar
• Van Cutsem E, Arends J. The causes and consequences of cancer-associated malnutrition. Eur J Oncol Nurs 2005;9:S51–63.
   PubMedGoogle Scholar
• Mathews EH, Liebenberg L, Pelzer R. High-glycolytic cancers and their interplay with the body's glucose demand and supply cycle. Med Hypoth 2011;76:157–65.
   PubMed Web of Science ®Google Scholar
• Medina RA, Owen GI. Glucose transporters: expression, regulation and cancer. Biol Res 2002;35:9–26.
   PubMed Web of Science ®Google Scholar
• Rivenzon-Segal D, Rushkin E, Polak-Charcon S, Degani H. Glucose transporters and transport kinetics in retinoic acid-differentiated T47D human breast cancer cells. Am J Physiol-Endocrinol Metabol 2000;279:E508–19.
   Google Scholar
• Pawar SK, Badhwar AJ, Kharas F, et al. Design, synthesis and evaluation of N-acetyl glucosamine (NAG)-PEG-doxorubicin targeted conjugates for anticancer delivery. Int J Pharmaceut 2012;436:183–93.
   PubMed Web of Science ®Google Scholar